Antidepressant treatment with fluoxetine during pregnancy and lactation modulates the gut microbiome and metabolome in a rat model relevant to depression
Date
2020Journal
Gut MicrobesPublisher
Taylor and Francis Inc.Type
Article
Metadata
Show full item recordAbstract
Up to 10% of women use selective serotonin reuptake inhibitor (SSRI) antidepressants during pregnancy and postpartum. Recent evidence suggests that SSRIs are capable of altering the gut microbiota. However, the interaction between maternal depression and SSRI use on bacterial community composition and the availability of microbiota-derived metabolites during pregnancy and lactation is not clear. We studied this using a rat model relevant to depression, where adult females with a genetic vulnerability and stressed as pups show depressive-like behaviors. Throughout pregnancy and lactation, females received the SSRI fluoxetine or vehicle. High-resolution 16S ribosomal RNA marker gene sequencing and targeted metabolomic analysis were used to assess the fecal microbiome and metabolite availability, respectively. Not surprisingly, we found that pregnancy and lactation segregate in terms of fecal microbiome diversity and composition, accompanied by changes in metabolite availability. However, we also showed that fluoxetine treatment altered important features of this transition from pregnancy to lactation most clearly in previously stressed dams, with lower fecal amino acid concentrations. Amino acid concentrations, in turn, correlated negatively with the relative abundance of bacterial taxa such as Prevotella and Bacteroides. Our study demonstrates an important relationship between antidepressant use during the perinatal period and maternal fecal metabolite availability in a rat model relevant to depression, possibly through parallel changes in the gut microbiome. Since microbial metabolites contribute to homeostasis and development, insults to the maternal microbiome by SSRIs might have health consequences for mother and offspring. Copyright 2020 The Author(s).Keyword
16S rRNAdepression
fecal metabolome
Fecal microbiome
fluoxetine
lactation
pregnancy
rat
serotonin transporter
SSRI antidepressants
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078398251&doi=10.1080%2f19490976.2019.1705728&partnerID=40&md5=b0e7f102873471457458d57b7b214052; http://hdl.handle.net/10713/11662ae974a485f413a2113503eed53cd6c53
10.1080/19490976.2019.1705728
Scopus Count
Collections
Related articles
- Fluoxetine during pregnancy: impact on fetal development.
- Authors: Morrison JL, Riggs KW, Rurak DW
- Issue date: 2005
- Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics.
- Authors: Yu M, Jia H, Zhou C, Yang Y, Zhao Y, Yang M, Zou Z
- Issue date: 2017 May 10
- Chronic fluoxetine treatment and maternal adversity differentially alter neurobehavioral outcomes in the rat dam.
- Authors: Pawluski JL, Charlier TD, Fillet M, Houbart V, Crispin HT, Steinbusch HW, van den Hove DL
- Issue date: 2012 Mar 1
- Interactions between maternal fluoxetine exposure, the maternal gut microbiome and fetal neurodevelopment in mice.
- Authors: Vuong HE, Coley EJL, Kazantsev M, Cooke ME, Rendon TK, Paramo J, Hsiao EY
- Issue date: 2021 Jul 23
- Perinatal fluoxetine dose-dependently affects prenatal stress-induced neurobehavioural abnormalities, HPA-axis functioning and underlying brain alterations in rat dams and their offspring.
- Authors: Amani M, Houwing DJ, Homberg JR, Salari AA
- Issue date: 2021 Sep